APO Research
Talk to an analyst

APO RESEARCH · REPORT

Living Biological Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Living Biological Drugs Market Outlook and Growth Opportunities 2026

16 January 2026213 pages

Choose your research edition.

Industry ResearchLiving Biological Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Living Biological Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Living Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Living Biological Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Living Biological Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Living Biological Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Living Biological Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Living Biological Drugs market include Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics, Infant Bacterial Therapeutics, Osel, Takeda, AOBiome and Synlogic, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Living Biological Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Living Biological Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Living Biological Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Living Biological Drugs market.

Living Biological Drugs Segment by Company

Ardeypharman

Miyarisan Pharmaceutical

Ferring Pharmaceuticals

Seres Therapeutics

Infant Bacterial Therapeutics

Osel

Takeda

AOBiome

Synlogic

Finch Therapeutics

Capsugel

Jeneil Biotech

UAS Labs

Biose

Cerbios-Pharma

Inpac Probiotics

NIZO

Winclove Probiotics

BJP Laboratories

Luina Bio

List Labs

MatriSys Bioscience

Living Biological Drugs Segment by Type

Single Strain

Multi Strain

Co-Culture

Living Biological Drugs Segment by Application

Digestive System

Urinary System

Skin System

Living Biological Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Living Biological Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Living Biological Drugs key companies, revenue, market share, and recent developments.

3. To split the Living Biological Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Living Biological Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Living Biological Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Living Biological Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Living Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Living Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Living Biological Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Living Biological Drugs industry.

Chapter 3: Detailed analysis of Living Biological Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Living Biological Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Living Biological Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Living Biological Drugs Industry Trends Table 2. Living Biological Drugs Industry Drivers Table 3. Living Biological Drugs Industry Opportunities and Challenges Table 4. Living Biological Drugs Industry Restraints Table 5. Global Living Biological Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Living Biological Drugs Revenue Share by Company (2021-2026) Table 7. Global Living Biological Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Living Biological Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Living Biological Drugs Company, Product Type & Application Table 10. Global Living Biological Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Living Biological Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Single Strain Table 15. Significant Companies of Multi Strain Table 16. Significant Companies of Co-Culture Table 17. Global Living Biological Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Living Biological Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Living Biological Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Living Biological Drugs Sales Value Share by Type (2021-2026) Table 21. Global Living Biological Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Digestive System Table 23. Significant Companies of Urinary System Table 24. Significant Companies of Skin System Table 25. Global Living Biological Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Living Biological Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Living Biological Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Living Biological Drugs Sales Value Share by Application (2021-2026) Table 29. Global Living Biological Drugs Sales Value Share by Application (2027-2032) Table 30. Global Living Biological Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Living Biological Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Living Biological Drugs Sales Value Share by Region (2021-2026) Table 33. Global Living Biological Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Living Biological Drugs Sales Value Share by Region (2027-2032) Table 35. Global Living Biological Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Living Biological Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Living Biological Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Living Biological Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Living Biological Drugs Sales Value Market Share by Country (2027-2032) Table 40. Ardeypharman Company Information Table 41. Ardeypharman Business Overview Table 42. Ardeypharman Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Ardeypharman Living Biological Drugs Product Portfolio Table 44. Ardeypharman Recent Development Table 45. Miyarisan Pharmaceutical Company Information Table 46. Miyarisan Pharmaceutical Business Overview Table 47. Miyarisan Pharmaceutical Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio Table 49. Miyarisan Pharmaceutical Recent Development Table 50. Ferring Pharmaceuticals Company Information Table 51. Ferring Pharmaceuticals Business Overview Table 52. Ferring Pharmaceuticals Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Ferring Pharmaceuticals Living Biological Drugs Product Portfolio Table 54. Ferring Pharmaceuticals Recent Development Table 55. Seres Therapeutics Company Information Table 56. Seres Therapeutics Business Overview Table 57. Seres Therapeutics Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Seres Therapeutics Living Biological Drugs Product Portfolio Table 59. Seres Therapeutics Recent Development Table 60. Infant Bacterial Therapeutics Company Information Table 61. Infant Bacterial Therapeutics Business Overview Table 62. Infant Bacterial Therapeutics Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio Table 64. Infant Bacterial Therapeutics Recent Development Table 65. Osel Company Information Table 66. Osel Business Overview Table 67. Osel Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Osel Living Biological Drugs Product Portfolio Table 69. Osel Recent Development Table 70. Takeda Company Information Table 71. Takeda Business Overview Table 72. Takeda Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Takeda Living Biological Drugs Product Portfolio Table 74. Takeda Recent Development Table 75. AOBiome Company Information Table 76. AOBiome Business Overview Table 77. AOBiome Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AOBiome Living Biological Drugs Product Portfolio Table 79. AOBiome Recent Development Table 80. Synlogic Company Information Table 81. Synlogic Business Overview Table 82. Synlogic Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Synlogic Living Biological Drugs Product Portfolio Table 84. Synlogic Recent Development Table 85. Finch Therapeutics Company Information Table 86. Finch Therapeutics Business Overview Table 87. Finch Therapeutics Living Biological Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Finch Therapeutics Living Biological Drugs Product Portfolio Table 89. Finch Therapeutics Recent Development Table 90. Capsugel Company Information Table 91. Capsugel Business Overview Table 92. Capsugel Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Capsugel Living Biological Drugs Product Portfolio Table 94. Capsugel Recent Development Table 95. Jeneil Biotech Company Information Table 96. Jeneil Biotech Business Overview Table 97. Jeneil Biotech Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Jeneil Biotech Living Biological Drugs Product Portfolio Table 99. Jeneil Biotech Recent Development Table 100. UAS Labs Company Information Table 101. UAS Labs Business Overview Table 102. UAS Labs Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. UAS Labs Living Biological Drugs Product Portfolio Table 104. UAS Labs Recent Development Table 105. Biose Company Information Table 106. Biose Business Overview Table 107. Biose Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Biose Living Biological Drugs Product Portfolio Table 109. Biose Recent Development Table 110. Cerbios-Pharma Company Information Table 111. Cerbios-Pharma Business Overview Table 112. Cerbios-Pharma Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Cerbios-Pharma Living Biological Drugs Product Portfolio Table 114. Cerbios-Pharma Recent Development Table 115. Inpac Probiotics Company Information Table 116. Inpac Probiotics Business Overview Table 117. Inpac Probiotics Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Inpac Probiotics Living Biological Drugs Product Portfolio Table 119. Inpac Probiotics Recent Development Table 120. NIZO Company Information Table 121. NIZO Business Overview Table 122. NIZO Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. NIZO Living Biological Drugs Product Portfolio Table 124. NIZO Recent Development Table 125. Winclove Probiotics Company Information Table 126. Winclove Probiotics Business Overview Table 127. Winclove Probiotics Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Winclove Probiotics Living Biological Drugs Product Portfolio Table 129. Winclove Probiotics Recent Development Table 130. BJP Laboratories Company Information Table 131. BJP Laboratories Business Overview Table 132. BJP Laboratories Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. BJP Laboratories Living Biological Drugs Product Portfolio Table 134. BJP Laboratories Recent Development Table 135. Luina Bio Company Information Table 136. Luina Bio Business Overview Table 137. Luina Bio Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Luina Bio Living Biological Drugs Product Portfolio Table 139. Luina Bio Recent Development Table 140. List Labs Company Information Table 141. List Labs Business Overview Table 142. List Labs Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. List Labs Living Biological Drugs Product Portfolio Table 144. List Labs Recent Development Table 145. MatriSys Bioscience Company Information Table 146. MatriSys Bioscience Business Overview Table 147. MatriSys Bioscience Living Biological Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. MatriSys Bioscience Living Biological Drugs Product Portfolio Table 149. MatriSys Bioscience Recent Development Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Living Biological Drugs Product Image Figure 2. Global Living Biological Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Living Biological Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Single Strain Image Figure 8. Multi Strain Image Figure 9. Co-Culture Image Figure 10. Global Living Biological Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Living Biological Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Living Biological Drugs Sales Value Share by Type (2021-2032) Figure 13. Digestive System Image Figure 14. Urinary System Image Figure 15. Skin System Image Figure 16. Global Living Biological Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Living Biological Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Living Biological Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Living Biological Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Living Biological Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Living Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Living Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Living Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Living Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Living Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Living Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Living Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Living Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Living Biological Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Living Biological Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Living Biological Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Living Biological Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Living Biological Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Single Strain
  • Multi Strain
  • Co-Culture
Applications
  • Digestive System
  • Urinary System
  • Skin System
Companies covered
  • Ardeypharman
  • Miyarisan Pharmaceutical
  • Ferring Pharmaceuticals
  • Seres Therapeutics
  • Infant Bacterial Therapeutics
  • Osel
  • Takeda
  • AOBiome
  • Synlogic
  • Finch Therapeutics
  • Capsugel
  • Jeneil Biotech
  • UAS Labs
  • Biose
  • Cerbios-Pharma
  • Inpac Probiotics
  • NIZO
  • Winclove Probiotics
  • BJP Laboratories
  • Luina Bio
  • List Labs
  • MatriSys Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Living Biological Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Living Biological Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Living Biological Drugs Market Dynamics
  1. 2.1 Living Biological Drugs Industry Trends
  2. 2.2 Living Biological Drugs Industry Drivers
  3. 2.3 Living Biological Drugs Industry Opportunities and Challenges
  4. 2.4 Living Biological Drugs Industry Restraints
3 Living Biological Drugs Market by Company
  1. 3.1 Global Living Biological Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Living Biological Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Living Biological Drugs Company Ranking (2024-2026)
  4. 3.4 Global Living Biological Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Living Biological Drugs Company Product Type and Application
  6. 3.6 Global Living Biological Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Living Biological Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Living Biological Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Living Biological Drugs Market by Type
  1. 4.1 Living Biological Drugs Type Introduction
  2. 4.1.1 Single Strain
  3. 4.1.2 Multi Strain
  4. 4.1.3 Co-Culture
  5. 4.2 Global Living Biological Drugs Sales Value by Type
  6. 4.2.1 Global Living Biological Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Living Biological Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Living Biological Drugs Sales Value Share by Type (2021-2032)
5 Living Biological Drugs Market by Application
  1. 5.1 Living Biological Drugs Application Introduction
  2. 5.1.1 Digestive System
  3. 5.1.2 Urinary System
  4. 5.1.3 Skin System
  5. 5.2 Global Living Biological Drugs Sales Value by Application
  6. 5.2.1 Global Living Biological Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Living Biological Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Living Biological Drugs Sales Value Share by Application (2021-2032)
6 Living Biological Drugs Regional Value Analysis
  1. 6.1 Global Living Biological Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Living Biological Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Living Biological Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Living Biological Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Living Biological Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Living Biological Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Living Biological Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Living Biological Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Living Biological Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Living Biological Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Living Biological Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Living Biological Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Living Biological Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Living Biological Drugs Sales Value Share by Country, 2025 VS 2032
7 Living Biological Drugs Country-level Value Analysis
  1. 7.1 Global Living Biological Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Living Biological Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Living Biological Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Living Biological Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Living Biological Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Living Biological Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Living Biological Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Living Biological Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Living Biological Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Living Biological Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Living Biological Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Living Biological Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Living Biological Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Living Biological Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Living Biological Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Living Biological Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Living Biological Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Living Biological Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Living Biological Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Living Biological Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Living Biological Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Living Biological Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Living Biological Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Living Biological Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Living Biological Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Living Biological Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Living Biological Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Living Biological Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Living Biological Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Living Biological Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Living Biological Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Living Biological Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Living Biological Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Living Biological Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ardeypharman
  2. 8.1.1 Ardeypharman Company Information
  3. 8.1.2 Ardeypharman Business Overview
  4. 8.1.3 Ardeypharman Living Biological Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ardeypharman Living Biological Drugs Product Portfolio
  6. 8.1.5 Ardeypharman Recent Developments
  7. 8.2 Miyarisan Pharmaceutical
  8. 8.2.1 Miyarisan Pharmaceutical Company Information
  9. 8.2.2 Miyarisan Pharmaceutical Business Overview
  10. 8.2.3 Miyarisan Pharmaceutical Living Biological Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio
  12. 8.2.5 Miyarisan Pharmaceutical Recent Developments
  13. 8.3 Ferring Pharmaceuticals
  14. 8.3.1 Ferring Pharmaceuticals Company Information
  15. 8.3.2 Ferring Pharmaceuticals Business Overview
  16. 8.3.3 Ferring Pharmaceuticals Living Biological Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ferring Pharmaceuticals Living Biological Drugs Product Portfolio
  18. 8.3.5 Ferring Pharmaceuticals Recent Developments
  19. 8.4 Seres Therapeutics
  20. 8.4.1 Seres Therapeutics Company Information
  21. 8.4.2 Seres Therapeutics Business Overview
  22. 8.4.3 Seres Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Seres Therapeutics Living Biological Drugs Product Portfolio
  24. 8.4.5 Seres Therapeutics Recent Developments
  25. 8.5 Infant Bacterial Therapeutics
  26. 8.5.1 Infant Bacterial Therapeutics Company Information
  27. 8.5.2 Infant Bacterial Therapeutics Business Overview
  28. 8.5.3 Infant Bacterial Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio
  30. 8.5.5 Infant Bacterial Therapeutics Recent Developments
  31. 8.6 Osel
  32. 8.6.1 Osel Company Information
  33. 8.6.2 Osel Business Overview
  34. 8.6.3 Osel Living Biological Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Osel Living Biological Drugs Product Portfolio
  36. 8.6.5 Osel Recent Developments
  37. 8.7 Takeda
  38. 8.7.1 Takeda Company Information
  39. 8.7.2 Takeda Business Overview
  40. 8.7.3 Takeda Living Biological Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Living Biological Drugs Product Portfolio
  42. 8.7.5 Takeda Recent Developments
  43. 8.8 AOBiome
  44. 8.8.1 AOBiome Company Information
  45. 8.8.2 AOBiome Business Overview
  46. 8.8.3 AOBiome Living Biological Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AOBiome Living Biological Drugs Product Portfolio
  48. 8.8.5 AOBiome Recent Developments
  49. 8.9 Synlogic
  50. 8.9.1 Synlogic Company Information
  51. 8.9.2 Synlogic Business Overview
  52. 8.9.3 Synlogic Living Biological Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Synlogic Living Biological Drugs Product Portfolio
  54. 8.9.5 Synlogic Recent Developments
  55. 8.10 Finch Therapeutics
  56. 8.10.1 Finch Therapeutics Company Information
  57. 8.10.2 Finch Therapeutics Business Overview
  58. 8.10.3 Finch Therapeutics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Finch Therapeutics Living Biological Drugs Product Portfolio
  60. 8.10.5 Finch Therapeutics Recent Developments
  61. 8.11 Capsugel
  62. 8.11.1 Capsugel Company Information
  63. 8.11.2 Capsugel Business Overview
  64. 8.11.3 Capsugel Living Biological Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Capsugel Living Biological Drugs Product Portfolio
  66. 8.11.5 Capsugel Recent Developments
  67. 8.12 Jeneil Biotech
  68. 8.12.1 Jeneil Biotech Company Information
  69. 8.12.2 Jeneil Biotech Business Overview
  70. 8.12.3 Jeneil Biotech Living Biological Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jeneil Biotech Living Biological Drugs Product Portfolio
  72. 8.12.5 Jeneil Biotech Recent Developments
  73. 8.13 UAS Labs
  74. 8.13.1 UAS Labs Company Information
  75. 8.13.2 UAS Labs Business Overview
  76. 8.13.3 UAS Labs Living Biological Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 UAS Labs Living Biological Drugs Product Portfolio
  78. 8.13.5 UAS Labs Recent Developments
  79. 8.14 Biose
  80. 8.14.1 Biose Company Information
  81. 8.14.2 Biose Business Overview
  82. 8.14.3 Biose Living Biological Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biose Living Biological Drugs Product Portfolio
  84. 8.14.5 Biose Recent Developments
  85. 8.15 Cerbios-Pharma
  86. 8.15.1 Cerbios-Pharma Company Information
  87. 8.15.2 Cerbios-Pharma Business Overview
  88. 8.15.3 Cerbios-Pharma Living Biological Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cerbios-Pharma Living Biological Drugs Product Portfolio
  90. 8.15.5 Cerbios-Pharma Recent Developments
  91. 8.16 Inpac Probiotics
  92. 8.16.1 Inpac Probiotics Company Information
  93. 8.16.2 Inpac Probiotics Business Overview
  94. 8.16.3 Inpac Probiotics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Inpac Probiotics Living Biological Drugs Product Portfolio
  96. 8.16.5 Inpac Probiotics Recent Developments
  97. 8.17 NIZO
  98. 8.17.1 NIZO Company Information
  99. 8.17.2 NIZO Business Overview
  100. 8.17.3 NIZO Living Biological Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 NIZO Living Biological Drugs Product Portfolio
  102. 8.17.5 NIZO Recent Developments
  103. 8.18 Winclove Probiotics
  104. 8.18.1 Winclove Probiotics Company Information
  105. 8.18.2 Winclove Probiotics Business Overview
  106. 8.18.3 Winclove Probiotics Living Biological Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Winclove Probiotics Living Biological Drugs Product Portfolio
  108. 8.18.5 Winclove Probiotics Recent Developments
  109. 8.19 BJP Laboratories
  110. 8.19.1 BJP Laboratories Company Information
  111. 8.19.2 BJP Laboratories Business Overview
  112. 8.19.3 BJP Laboratories Living Biological Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 BJP Laboratories Living Biological Drugs Product Portfolio
  114. 8.19.5 BJP Laboratories Recent Developments
  115. 8.20 Luina Bio
  116. 8.20.1 Luina Bio Company Information
  117. 8.20.2 Luina Bio Business Overview
  118. 8.20.3 Luina Bio Living Biological Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Luina Bio Living Biological Drugs Product Portfolio
  120. 8.20.5 Luina Bio Recent Developments
  121. 8.21 List Labs
  122. 8.21.1 List Labs Company Information
  123. 8.21.2 List Labs Business Overview
  124. 8.21.3 List Labs Living Biological Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 List Labs Living Biological Drugs Product Portfolio
  126. 8.21.5 List Labs Recent Developments
  127. 8.22 MatriSys Bioscience
  128. 8.22.1 MatriSys Bioscience Company Information
  129. 8.22.2 MatriSys Bioscience Business Overview
  130. 8.22.3 MatriSys Bioscience Living Biological Drugs Revenue and Gross Margin (2021-2026)
  131. 8.22.4 MatriSys Bioscience Living Biological Drugs Product Portfolio
  132. 8.22.5 MatriSys Bioscience Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst